Clascoterone

Introduction Overview

Generic Name

clascoterone

Brand Name

Winlevi

Dosage Form

cream 1%

Drug Class

Topical acne agents

Pharmacokinetics

Absorption: Clascoterone, the active ingredient in Winlevi cream, is a topical androgen receptor inhibitor designed for local application to the skin. After topical application, systemic absorption of clascoterone is minimal due to its pharmacologic formulation and metabolism in the skin. This limited systemic absorption reduces potential systemic adverse effects. The cream is applied twice daily to affected skin areas, facilitating adequate local drug concentration in sebaceous glands and hair follicles where it exerts its effects. Factors such as skin integrity, presence of eczema, cuts, or sunburn can influence drug absorption, often increasing systemic exposure if the skin barrier is compromised.

Distribution: Due to limited systemic absorption, clascoterone demonstrates minimal distribution into systemic circulation. Within the skin, clascoterone targets androgen receptors located in sebaceous glands and hair follicles. Its local activity allows it to modulate sebaceous gland function and inflammation that contribute to acne pathogenesis. There is negligible penetration into deeper tissues or distant organs when used topically as directed. Distribution within the epidermis and dermis is adequate to exert androgen receptor antagonism.

Metabolism: Clascoterone undergoes extensive in situ metabolism in the skin where it is topically applied. The drug is rapidly hydrolyzed to its active form, cortexolone (also known as 11-deoxycortisol), which binds androgen receptors competitively. Due to its topical use, first-pass hepatic metabolism is largely avoided. Any absorbed clascoterone is expected to be further metabolized hepatically via conventional steroid metabolic pathways, though systemic levels are generally undetectable at therapeutic topical doses.

Elimination: The primary elimination pathway for clascoterone after topical application involves local metabolism in the skin followed by systemic clearance of any absorbed metabolites primarily via renal excretion. Because systemic levels remain low, elimination half-life in plasma has not been well characterized. Local metabolism reduces systemic clearance requirements. Clinical pharmacokinetic studies indicate no accumulation with twice-daily dosing over typical treatment courses for acne vulgaris.

Dosage Forms

Available Dosage Forms: Winlevi is available as a topical cream containing 1% clascoterone as the active ingredient. It is formulated for cutaneous application and supplied in tubes suitable for precise dosing. The cream base includes inactive ingredients such as cetyl alcohol, citric acid monohydrate, edetate disodium, mineral oil, mono- and di-glycerides, polysorbate 80, propylene glycol, purified water, and vitamin E.

Dosages for Adults and Adolescents: The FDA-approved dosage regimen for Winlevi cream is to apply a thin layer of 1% clascoterone cream twice daily to the affected areas of the skin. This regimen applies to patients 12 years of age and older. Treatment duration in clinical trials was 12 weeks, during which significant reductions in acne lesion counts and improvements in severity grading were demonstrated. Patients are instructed to wash and dry skin gently before application.

Specific Patient Populations: Use in pediatric patients under 12 years of age has not been established and is not recommended. Caution is advised in patients with skin barrier damage such as eczema, cuts, abrasions, or sunburn due to potential increased systemic absorption and risk of hypothalamic-pituitary-adrenal (HPA) axis suppression. In pregnancy and breastfeeding, the effects are unknown; therefore, Winlevi should be used only if clearly needed and after consultation with a healthcare provider. Systemic exposure is minimal, but caution remains prudent.

Storage and Handling: Before dispensing, Winlevi cream should be stored refrigerated between 2°C and 8°C (36°F to 46°F) and should not be frozen. After dispensing to the patient, it can be stored at room temperature between 20°C and 25°C (68°F to 77°F), without freezing. Unused portions should be discarded 180 days after dispensing or one month after opening, whichever is sooner.

Mechanism Of Action

Clascoterone, the active moiety in Winlevi cream, is a novel topical androgen receptor antagonist that exerts its therapeutic effects primarily by inhibiting androgen receptor activation in the skin. Acne pathogenesis is influenced by androgenic stimulation of sebaceous glands, leading to increased sebum production and follicular hyperkeratinization. By competitively binding to androgen receptors located in sebaceous glands and hair follicle epithelium, clascoterone prevents androgens such as dihydrotestosterone (DHT) from binding and activating downstream signaling pathways.

At the molecular level, clascoterone inhibits transcriptional events triggered by androgen receptor activation, resulting in decreased lipogenesis within sebocytes. Moreover, clascoterone modulates inflammatory pathways induced by androgens, reducing the production of pro-inflammatory cytokines and chemokines involved in acne lesion formation. This dual action on sebum production and inflammation contributes to clinically observed improvements in acne severity.

Clascoterone’s topical application limits systemic exposure, allowing targeted modulation of local androgenic effects in the pilosebaceous unit while minimizing systemic hormonal side effects associated with oral antiandrogens. Comparative studies suggest clascoterone achieves androgen receptor blockade without the systemic adverse effects seen with oral agents such as spironolactone, supporting its safety profile.

Clinical trials demonstrate that twice-daily topical application of Winlevi cream leads to significant reductions in inflammatory and non-inflammatory acne lesions after four weeks of use, with maximum effect at approximately three months. This clinical efficacy aligns with the pharmacodynamic action of clascoterone at the receptor and cellular levels, establishing it as an effective topical antiandrogen agent in acne management.

Pharmacological Actions

Selective androgen receptor inhibition in sebaceous glands and hair follicles
Reduction of sebum production via blockade of androgen-mediated lipogenesis
Anti-inflammatory effects by decreasing pro-inflammatory cytokine production in the skin
Topical mechanism reduces systemic androgen receptor activation avoiding systemic hormonal side effects
Competitive antagonism of androgen receptors preventing downstream transcriptional signaling
Modulation of sebocyte activity contributing to normalization of follicular keratinization
Minimal systemic absorption enhancing localized efficacy and safety
Improvement in both inflammatory and non-inflammatory acne lesion counts
Maintaining skin barrier integrity when used as directed
No immunosuppressive effects noted with topical application

Therapeutic Or Clinical Uses

Topical treatment of acne vulgaris in patients aged 12 years and older
Reduction of inflammatory acne lesions including papules and pustules
Reduction of non-inflammatory lesions such as comedones
Adjunctive therapy to standard acne treatments to improve clinical outcomes
Treatment of mild to moderate acne involving sebaceous gland hyperactivity
Alternative for patients who cannot tolerate or are contraindicated for systemic antiandrogens
Suitable for long-term topical therapy given favorable safety profile
Use in patients with androgen-driven acne where hormonal modulation is beneficial
Reduction of acne-associated skin oiliness and erythema
Improvement in overall skin clarity and reduction in acne-related inflammation

Side Or Adverse Effects

Local skin irritation at the application site including redness and burning
Itching or pruritus localized to treated areas
Skin dryness and scaling or peeling during therapy
Potential for hypothalamic-pituitary-adrenal (HPA) axis suppression with extensive application or prolonged use
Rare reports of adrenal insufficiency symptoms leading to cessation of treatment
Increased sensitivity or irritation if applied to broken skin, eczema, sunburn, or abrasions
Accidental contact with eyes, mouth, or mucous membranes causing irritation
Possible allergic reactions or contact dermatitis in sensitive individuals
Transient worsening of acne lesions during initial therapy in some patients
Skin photosensitivity is not commonly reported but sun protection is advised

Precautions

Avoid use on skin areas with cuts, abrasions, eczema, or sunburned skin to prevent increased absorption
Do not apply the cream near eyes, lips, mouth, or mucous membranes to avoid irritation
Use cautiously in patients with compromised skin barrier function
Monitor patients for signs of HPA axis suppression if large surface areas are treated or if occlusive dressings are used
Inform healthcare provider about all concomitant medications and medical conditions before starting treatment
Advise patients to wash hands immediately after application to prevent inadvertent mucous membrane exposure
Avoid concomitant use of topical products that excessively dry or irritate the skin such as medicated or abrasive soaps, products with high alcohol content, or astringents
Safety in pregnancy is not established; use only if potential benefit justifies potential risk
Unknown if the drug is excreted in breast milk; use caution during breastfeeding and consult healthcare provider
Instruct patients regarding proper application technique and adherence to avoid misuse

Warnings

For topical use only; do not apply in or near eyes, mouth, vagina, or other mucous membranes
Risk of hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with widespread or prolonged use or use under occlusive dressings
Discontinue treatment and seek medical advice if signs of adrenal insufficiency develop
Store properly to maintain drug stability; do not freeze after dispensing
Avoid concurrent use with other topical acne products that could cause additive irritation unless directed by a healthcare provider
Not established for use in patients younger than 12 years old
Avoid exposure to skin products containing high amounts of alcohol or irritants during treatment
Carefully assess skin condition prior to treatment initiation; avoid use on damaged or inflamed skin
Monitor for adverse skin reactions frequently during treatment course
Patients should be advised of potential local skin reactions which often resolve with continued use

Contraindication

Known hypersensitivity or allergy to clascoterone or any component of the cream formulation
Use on mucous membranes such as eyes, mouth, vagina, or in open wounds or damaged skin
Use in patients with active skin infections at the treatment site
Contraindicated in children under 12 years of age due to lack of established safety and efficacy
Avoid use in patients with adrenal insufficiency or other disorders of hormone regulation without specialist oversight
Not to be used concomitantly with agents that may exacerbate skin irritation without careful clinical assessment
Contraindicated if history of severe contact dermatitis or allergic reaction to topical formulations
Avoid use in pregnancy unless clearly indicated and benefits outweigh potential risks
Contraindicated in combination with systemic antiandrogens without physician supervision

Drug Interactions

Avoid concomitant use with topical products that excessively dry or irritate the skin, such as medicated or abrasive soaps and cleansers
Avoid using skin products containing high amounts of alcohol or astringents concurrently to minimize irritation
Possible additive local irritation with other topical retinoids or acne agents; spacing or alternating use may be necessary
No significant systemic drug interactions are expected due to minimal systemic absorption
Caution if combined with systemic antiandrogens or hormonal therapies; clinical monitoring advised
No known interactions with oral antibiotics or other standard acne treatments when used topically
Concurrent use with products impairing skin barrier may increase systemic absorption risk
Drug interaction profile continues to be characterized; clinicians should monitor patient responses
Advise patients to report side effects or unusual skin reactions during combined topical regimens

Preparations Of The Drug

Winlevi 1% topical cream, supplied in tubes for cutaneous application
Formulated with inactive ingredients including cetyl alcohol, citric acid monohydrate, edetate disodium, mineral oil, mono- and di-glycerides, polysorbate 80, propylene glycol, purified water, and vitamin E
Applied as a thin layer twice daily to affected skin areas
Packaging designed to maintain product stability between refrigerated storage prior to dispensing and room temperature storage after dispensing
Cream base designed for good skin absorption with minimal irritation
Non-greasy texture suitable for facial and other acne-prone areas
No preservatives known to cause significant allergenicity
Manufactured and distributed by Sun Pharmaceutical Industries Limited/Inc.
Available only by prescription with guidance on proper use and storage
Discard unused cream 180 days after dispensing or 1 month after first opening, whichever occurs first